Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists

Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)

Carl Wagner, Peter Jurutka, Pamela Marshall, Thomas L. Groy, Arjan Van Der Vaart, Joseph W. Ziller, Julie K. Furmick, Mark E. Graeber, Erik Matro, Belinda V. Miguel, Ivy T. Tran, Jungeun Kwon, Jamie N. Tedeschi, Shahram Moosavi, Amina Danishyar, Joshua S. Philp, Reina O. Khamees, Jevon N. Jackson, Darci K. Grupe, Syed L. Badshah & 1 others Justin W. Hart

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

This report describes the synthesis of analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X receptor (RXR)-specific agonists. Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can cause side effects such as hypothyroidism and increased triglyceride concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors. The novel analogues in the present study have been evaluated forRXR activation in an RXR mammalian-2-hybrid assay as well as an RXRE-mediated transcriptional assay and for their ability to induce apoptosis as well as for their mutagenicity and cytotoxicity. Analysis of 11 novel compounds revealed the discovery of three analogues that best induce RXR-mediated transcriptional activity, stimulate apoptosis, have comparable Ki and EC50 values to 1, and are selective RXR agonists. Our experimental approach suggests that rational drug design can develop new rexinoids with improved biological properties.

Original languageEnglish (US)
Pages (from-to)5950-5966
Number of pages17
JournalJournal of Medicinal Chemistry
Volume52
Issue number19
DOIs
StatePublished - Oct 8 2009

Fingerprint

Retinoid X Receptors
Benzoic Acid
Apoptosis
Cutaneous T-Cell Lymphoma
Drug Design
Cytoplasmic and Nuclear Receptors
Hypothyroidism
Triglycerides
bexarotene

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists : Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). / Wagner, Carl; Jurutka, Peter; Marshall, Pamela; Groy, Thomas L.; Van Der Vaart, Arjan; Ziller, Joseph W.; Furmick, Julie K.; Graeber, Mark E.; Matro, Erik; Miguel, Belinda V.; Tran, Ivy T.; Kwon, Jungeun; Tedeschi, Jamie N.; Moosavi, Shahram; Danishyar, Amina; Philp, Joshua S.; Khamees, Reina O.; Jackson, Jevon N.; Grupe, Darci K.; Badshah, Syed L.; Hart, Justin W.

In: Journal of Medicinal Chemistry, Vol. 52, No. 19, 08.10.2009, p. 5950-5966.

Research output: Contribution to journalArticle

Wagner, C, Jurutka, P, Marshall, P, Groy, TL, Van Der Vaart, A, Ziller, JW, Furmick, JK, Graeber, ME, Matro, E, Miguel, BV, Tran, IT, Kwon, J, Tedeschi, JN, Moosavi, S, Danishyar, A, Philp, JS, Khamees, RO, Jackson, JN, Grupe, DK, Badshah, SL & Hart, JW 2009, 'Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists: Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)', Journal of Medicinal Chemistry, vol. 52, no. 19, pp. 5950-5966. https://doi.org/10.1021/jm900496b
Wagner, Carl ; Jurutka, Peter ; Marshall, Pamela ; Groy, Thomas L. ; Van Der Vaart, Arjan ; Ziller, Joseph W. ; Furmick, Julie K. ; Graeber, Mark E. ; Matro, Erik ; Miguel, Belinda V. ; Tran, Ivy T. ; Kwon, Jungeun ; Tedeschi, Jamie N. ; Moosavi, Shahram ; Danishyar, Amina ; Philp, Joshua S. ; Khamees, Reina O. ; Jackson, Jevon N. ; Grupe, Darci K. ; Badshah, Syed L. ; Hart, Justin W. / Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists : Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). In: Journal of Medicinal Chemistry. 2009 ; Vol. 52, No. 19. pp. 5950-5966.
@article{4adfc5842459440889eec7e7c32687ab,
title = "Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists: Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)",
abstract = "This report describes the synthesis of analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X receptor (RXR)-specific agonists. Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can cause side effects such as hypothyroidism and increased triglyceride concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors. The novel analogues in the present study have been evaluated forRXR activation in an RXR mammalian-2-hybrid assay as well as an RXRE-mediated transcriptional assay and for their ability to induce apoptosis as well as for their mutagenicity and cytotoxicity. Analysis of 11 novel compounds revealed the discovery of three analogues that best induce RXR-mediated transcriptional activity, stimulate apoptosis, have comparable Ki and EC50 values to 1, and are selective RXR agonists. Our experimental approach suggests that rational drug design can develop new rexinoids with improved biological properties.",
author = "Carl Wagner and Peter Jurutka and Pamela Marshall and Groy, {Thomas L.} and {Van Der Vaart}, Arjan and Ziller, {Joseph W.} and Furmick, {Julie K.} and Graeber, {Mark E.} and Erik Matro and Miguel, {Belinda V.} and Tran, {Ivy T.} and Jungeun Kwon and Tedeschi, {Jamie N.} and Shahram Moosavi and Amina Danishyar and Philp, {Joshua S.} and Khamees, {Reina O.} and Jackson, {Jevon N.} and Grupe, {Darci K.} and Badshah, {Syed L.} and Hart, {Justin W.}",
year = "2009",
month = "10",
day = "8",
doi = "10.1021/jm900496b",
language = "English (US)",
volume = "52",
pages = "5950--5966",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists

T2 - Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)

AU - Wagner, Carl

AU - Jurutka, Peter

AU - Marshall, Pamela

AU - Groy, Thomas L.

AU - Van Der Vaart, Arjan

AU - Ziller, Joseph W.

AU - Furmick, Julie K.

AU - Graeber, Mark E.

AU - Matro, Erik

AU - Miguel, Belinda V.

AU - Tran, Ivy T.

AU - Kwon, Jungeun

AU - Tedeschi, Jamie N.

AU - Moosavi, Shahram

AU - Danishyar, Amina

AU - Philp, Joshua S.

AU - Khamees, Reina O.

AU - Jackson, Jevon N.

AU - Grupe, Darci K.

AU - Badshah, Syed L.

AU - Hart, Justin W.

PY - 2009/10/8

Y1 - 2009/10/8

N2 - This report describes the synthesis of analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X receptor (RXR)-specific agonists. Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can cause side effects such as hypothyroidism and increased triglyceride concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors. The novel analogues in the present study have been evaluated forRXR activation in an RXR mammalian-2-hybrid assay as well as an RXRE-mediated transcriptional assay and for their ability to induce apoptosis as well as for their mutagenicity and cytotoxicity. Analysis of 11 novel compounds revealed the discovery of three analogues that best induce RXR-mediated transcriptional activity, stimulate apoptosis, have comparable Ki and EC50 values to 1, and are selective RXR agonists. Our experimental approach suggests that rational drug design can develop new rexinoids with improved biological properties.

AB - This report describes the synthesis of analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X receptor (RXR)-specific agonists. Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can cause side effects such as hypothyroidism and increased triglyceride concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors. The novel analogues in the present study have been evaluated forRXR activation in an RXR mammalian-2-hybrid assay as well as an RXRE-mediated transcriptional assay and for their ability to induce apoptosis as well as for their mutagenicity and cytotoxicity. Analysis of 11 novel compounds revealed the discovery of three analogues that best induce RXR-mediated transcriptional activity, stimulate apoptosis, have comparable Ki and EC50 values to 1, and are selective RXR agonists. Our experimental approach suggests that rational drug design can develop new rexinoids with improved biological properties.

UR - http://www.scopus.com/inward/record.url?scp=70349645985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349645985&partnerID=8YFLogxK

U2 - 10.1021/jm900496b

DO - 10.1021/jm900496b

M3 - Article

VL - 52

SP - 5950

EP - 5966

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -